David Cade, the chief medical officer of Melbourne-based Telix Pharmaceuticals, traveled a long way to the American Society of Clinical Oncology meeting in Chicago with a singular goal in mind: spread the word about Telix’s pivotal trial for a potential challenger to Novartis’ Pluvicto.